Writing

• Pharma Marketing
• 23 September 2026

UK pharma advertising rules: the ABPI Code and MHRA explained

In the UK, pharmaceutical companies cannot advertise prescription-only medicines to the public. The ban is in the Human Medicines Regulations 2012 and the MHRA enforces it. Promotion to health professionals is allowed, but it must match the product’s licence, be accurate and balanced, and for most companies it must also follow the ABPI Code of Practice, which the PMCPA polices.

The legal sentence doing most of the work is short. Regulation 284 says: “A person may not publish an advertisement that is likely to lead to the use of a prescription only medicine.” Breaching the advertising regulations is a criminal offence, and on indictment the penalty can be a fine, up to two years in prison, or both. The self-regulatory side is busy too: the PMCPA received 262 complaints in 2025.

What are the current regulations for pharmaceutical advertising in the UK?

There are two layers, and they overlap on purpose: the law plus the MHRA, and the ABPI Code plus the PMCPA. The MHRA’s Blue Guide describes it as “a long established system of self-regulation supported by the statutory role of the MHRA, acting on behalf of Health Ministers.”

The law: Part 14 of the Human Medicines Regulations 2012

Part 14 of the Regulations covers advertising, and a handful of provisions do most of the work for a marketer:

• Regulation 279: no advertising of a medicine in Great Britain unless a relevant authorisation is in force (for most of us, a UK marketing authorisation). Northern Ireland has its own list.
• Regulation 280: adverts must comply with the summary of product characteristics (SmPC), must encourage rational use “by presenting it objectively and without exaggerating its properties”, and must not mislead.
• Regulation 284: the ban on advertising prescription-only medicines (POMs) to the public, with exceptions for approved vaccination campaigns (regulation 292) and campaigns about the spread of pathogenic agents (regulation 291A).
• Regulations 293 to 300: advertising to people qualified to prescribe or supply, covering the information an advert must contain, free samples, sales representatives, and inducements and hospitality.
• Regulation 303: offences and penalties.

The MHRA and the Blue Guide

The MHRA’s page Advertise your medicines (updated 11 April 2025) says it may vet advertising before publication for a newly licensed product, a reclassified product, or a company with previous breaches. It can require material to be amended or withdrawn, corrections published, or future advertising submitted for vetting, though most complaints end in informal agreement, and it aims to finish an investigation within one month.

The Blue Guide, last updated online on 28 March 2025, is the MHRA’s guidance on how it reads the law. It isn’t law, but it is the regulator’s own written interpretation. It defines advertising broadly, as “any thing or any activity which is intended to encourage prescription or supply by healthcare professionals and use of medicines by the general public”, with rep visits, samples and meeting sponsorship as examples.

The ABPI Code and the PMCPA

The ABPI (Association of the British Pharmaceutical Industry) writes the Code. The PMCPA (Prescription Medicines Code of Practice Authority) administers it, rules on complaints and, according to the Code’s introduction, “operates independently of the ABPI itself”. Abiding by the Code is a condition of ABPI membership, and over sixty non-member companies have formally agreed to it. It “reflects and extends beyond the relevant UK law”, most visibly on certification and payment disclosure.

Can pharma companies advertise to the public in the UK?

Not for prescription-only medicines. The MHRA’s wording: “You can’t advertise prescription-only medicines (POMs) to the general public but you can promote them to healthcare professionals.” Pharmacy and general sale medicines can be advertised to the public, and the PAGB (the consumer healthcare trade body) reviews its members’ ads. Clause 26.1 of the Code puts it in ten words: “Prescription only medicines must not be advertised to the public.”

Under Clause 26.2, information about POMs given to the public must be factual and balanced, must not raise unfounded hopes of successful treatment or mislead about safety, and must not be designed to encourage people to ask their health professional for a specific POM. Clause 26.5 says requests from the public for advice on personal medical matters must be refused, with the enquirer pointed to their own doctor or other health professional.

Disease awareness campaigns and where they cross the line

The Code’s supplementary information allows disease awareness campaigns “provided that the purpose is to encourage members of the public to seek treatment for their symptoms while in no way promoting the use of a specific medicine.” The Blue Guide warns against brand names and against describing treatment in a way that points to one product. The campaign for a condition where your drug is the only treatment, signed off with “ask your doctor about treatment options”, is exactly the kind of campaign those warnings describe.

Press work counts. In a ruling the PMCPA publicised in February 2026, Sanofi breached Clauses 26.1 and 2, among others, over a UK Sunday newspaper article based on an interview with a senior leader, which was ruled to have promoted Beyfortus (nirsevimab) with misleading claims and to have disparaged Pfizer’s vaccine. Somebody in comms presumably filed that under earned media.

The MHRA polices non-industry advertisers too. In September 2025, alongside the ASA and the General Pharmaceutical Council, it reaffirmed the rules on prescription weight-loss medicines, said it had acted against more than 25 businesses that year, and named phrases such as “weight-loss injection” and “GLP-1” as problems. That is regulation 284’s “likely to lead to the use of” in practice: you don’t need to name the brand to break it.

ABPI Code explained: what it requires when you promote to health professionals

The current edition is the 2024 ABPI Code of Practice, published on 23 September 2024, in operation from 1 October 2024 and in full force from 1 January 2025 after a transition period. The PMCPA has since consulted on changes to its Constitution and Procedure (that consultation has closed), so check the PMCPA’s Code page and its Q&As before each campaign.

Certification (Clause 8)

Clause 8.1 says promotional material must not be issued until its final form has been certified by a UK-registered medical practitioner or pharmacist (or a UK-registered dentist for dental-only products). Final form means no further changes, so any edit after sign-off creates a new version that needs certifying again. Material in use must be recertified at least every two years (Clause 8.5), and certificates kept for at least three years after final use (Clause 8.6).

Prescribing information (Clause 12)

Clause 12.1 requires clear, legible prescribing information in all promotional material except abbreviated advertisements. Clause 12.2 lists the contents, from legal classification and cost excluding VAT to adverse reactions and the marketing authorisation number. The 2024 edition’s headline change lets printed material carry a QR code to the prescribing information, and digital material on the recipient’s device use a single-click link. You also need the adverse event reporting statement pointing to the MHRA Yellow Card scheme, the black triangle where required (Clause 12.7), and the date the material was created or last revised (Clause 12.5).

Claims, comparisons and the licence (Clauses 6 and 11)

Clause 6.1 requires claims to be “accurate, balanced, fair, objective and unambiguous” and based on an up-to-date evaluation of all the evidence, and Clause 6.2 says they must be capable of substantiation. Clause 6.4 bans “safe” without qualification, Clause 6.5 bans “new” after twelve months of general availability, and Clause 6.6 bans disparaging competitors’ medicines. The supplementary information to 6.1 rules out hanging comparisons, where a medicine is “better” or “stronger” without saying than what. Better than the competitor, placebo, last year’s formulation, a cup of tea? If the copy doesn’t say, the Panel won’t guess in your favour.

Clause 11.1 bans promotion before the marketing authorisation is granted, and Clause 11.2 requires promotion to follow its terms. The supplementary information is blunt: “The promotion of indications not covered by the marketing authorisation for a medicine is prohibited.”

High standards and declaring involvement (Clause 5)

Clause 5.1 requires high standards at all times, Clause 5.3 requires material to recognise “the special nature of medicines”, and Clause 5.6 requires sponsored material to declare the company’s involvement clearly. For the channel side of HCP work, see how pharma engages HCPs digitally in the UK.

Where do UK pharma marketing rules catch people out on social media?

The PMCPA published revised social media guidance on 4 February 2026, updating sections on the Code’s scope, disease awareness and influencer collaborations, misinformation, clinical trial recruitment and pharmacovigilance. Read the guidance itself, not summaries of it (this one included).

Employee likes keep producing case reports. In AUTH/3774/6/23 (completed October 2024), two senior UK AstraZeneca employees had liked LinkedIn posts about unlicensed combinations involving Imfinzi (durvalumab). The Panel said their engagement “would have proactively disseminated the material to their LinkedIn connections in the UK, which likely included members of the public”, and ruled breaches including Clauses 26.1 and 2. In CASE/0563/04/25 (completed 17 October 2025), three UK employees liked an external researcher’s post about oncology trials. They didn’t write, share or comment on it, and Clause 26.1 was still breached because not all their connections would be health professionals. Congratulations to the like button, now the most expensive click in the building, and one we’ve all pressed on autopilot on the Monday commute.

A PMCPA pilot policy from June 2025 lets case managers decline complaints about social media activity dated more than six months before the complaint (two years for other activity), with discretion for patient safety and public interest.

What does the Code say about patient organisations and Disclosure UK?

Clause 27.1 says companies must not promote, or ask for promotion of, a particular POM through patient organisations, and must respect their independence. Clause 27.2 requires a written agreement for each donation, grant or sponsorship, and payments to patient organisations are disclosed annually under Clause 29.

Payments to health professionals and healthcare organisations go on Disclosure UK, the ABPI’s public database. The ABPI and PMCPA’s June 2026 update, by Dr Amit Aggarwal of the ABPI and PMCPA chief executive Alex Fell, reported £929.6 million in transfers of value for 2025, 70 per cent of it R&D, from 150 companies, with an estimated 93.6 per cent of health professionals named against non-R&D values. Advisory boards, speaker fees and sponsored congress places all end up there, next to a real person’s name.

How do the PMCPA complaints process and sanctions work?

Complaints come from health professionals, the public, competitors and employees. The Code of Practice Panel rules first, and either side can appeal to the Appeal Board, which has an independent, legally qualified chair, eight independent and eight industry members, and always sits with an independent majority. The 2024 procedure added an abridged route for less serious complaints, and completed case reports are published.

The PMCPA Annual Report 2025 reports 262 complaints in 2025 (264 in 2024) and at least one breach in 58% of cases received in 2024. Cases received in 2024 took 52.2 weeks on average, long enough for the campaign, the brand manager and possibly the brand to have moved on before the ruling lands, though open complaints fell from 155 to 81 during 2025.

Sanctions include:

• A written undertaking to stop the practice.
• Administrative charges per matter ruled in breach: £5,000 for members accepting a ruling, £13,000 after a failed appeal (£6,000 and £14,000 for non-members), plus £4,000 towards press advertising after a Clause 2 breach, public reprimand or corrective statement.
• An audit of company procedures, which can lead to pre-vetting.
• Public reprimand, corrective statements and recovery of material.
• Advertisements in the medical, pharmaceutical and nursing press (Sanofi’s was due in the BMJ and Nursing Standard).
• Referral to the ABPI Board, which can suspend or expel a company.

The April 2026 Theramex ruling shows how unglamorous a Clause 2 breach can be: a pregnancy contraindication missing from conference advertising for Yselty, and prescribing information for Evorel and Intrarosa out of date for several years. The Appeal Board issued a public reprimand and required an audit before Theramex, which withdrew from self-regulation on 28 January 2026, could rejoin.

Ethical considerations for promoting prescription medicines

The prescriber chooses, the patient takes it, and the product can do harm. A patient can’t judge a POM the way they judge a sofa, so the law routes information through a prescriber. Regulation 280’s “rational use” and Clause 5.3’s “special nature of medicines” are the ethical centre, and most detailed clauses apply those two ideas to a particular format.

The questions I’d put to any campaign are plain ones. Would a prescriber who read only the headline get an accurate picture of benefit and risk? Does the disease awareness campaign push people toward a conversation or toward a brand? Is the fee buying expertise or goodwill? And would we be comfortable reading it in a published case report? Launch pressure is where I’d expect these questions to get skipped, which is part of why I wrote about market access strategy for a new drug in the UK.

Where does AI-generated content fit into certification?

A PMCPA Q&A last revised in June 2025 says the Code’s requirements “remain unchanged”, the company stays responsible, and Clause 8.1 certification “cannot be fulfilled solely by the use of AI”. It expects policies, training and risk assessment for AI use, and says it may examine them when a complaint involves AI.

So a language model can draft copy or check claims against references, but it isn’t on the GMC register, however confident it sounds. I’d argue AI makes certification matter more, because fluent copy produced fast is exactly where an unqualified superlative or hanging comparison hides. Treat the output as a first draft from a junior writer who has never read the SmPC, and build the rules into the prompt:

Draft promotional copy for UK health professionals for [product].
Use only claims supported by the attached SmPC and references, and cite
reference and page for each. Mention no indication, dose or population
outside the SmPC. Do not use "safe" or "new". Name the comparator in every
comparison. Flag any sentence you are unsure is supported instead of
rewording it to sound more certain.

Keep the tool, prompts and references in the job bag so the signatory can see them. The general version of that checkpoint design is in how to build an AI marketing workflow, and the team-adoption side in my ACTAsia case study.

What are the compliance considerations for pharma marketing in the UK? A campaign checklist

1. Confirm a UK marketing authorisation is in force for the territory (GB, NI or both) and every message sits inside the SmPC.
2. Define the audience. If any channel could reach the public, the POM ban applies.
3. Test every claim against Clause 6: substantiated, balanced, current, no unqualified “safe”, no stale “new”, every comparator named.
4. Add prescribing information (text, QR code or single-click link by format), the adverse event statement, the black triangle if required and the date.
5. Declare company involvement on anything sponsored.
6. Certify the final form, including every digital variant, and diary recertification within two years.
7. Brief staff and agencies on personal social media, including likes and reposts, in line with your SOPs.
8. Strip brand cues from disease awareness and make the call to action “see a health professional”.
9. Put written agreements in place for speakers, advisory boards and patient groups, and plan the Disclosure UK entry from the start.
10. Record AI tools, prompts and sources, and keep certificates for at least three years after final use.

Common pitfalls

The ones I’d watch hardest are employee likes and reposts, off-label drift in congress coverage, hanging comparisons that sneak in during copy polishing, out-of-date prescribing information on material nobody remembered was live, media interviews treated as “comms, not promotion”, and edits after certification. When a case lands we blame the agency, the SOP, the signatory, probably the conference Wi-Fi, but the Theramex and AstraZeneca reports read more like ordinary process failures than anything exotic.

This is an explainer, not legal or compliance advice: check the current Code, the PMCPA’s latest Q&As and your company SOPs. A useful next step is to pull a list of every live piece of material and ask which of it hasn’t been looked at since the day it was certified.

FAQs

Is the ABPI Code legally binding?

No, the ABPI Code is self-regulation rather than law. ABPI member companies must comply with it and non-members can agree to be bound. It sits alongside the Human Medicines Regulations 2012, which are law and are enforced by the MHRA. Breaching the Code can lead to PMCPA sanctions such as administrative charges, audits, public reprimands and advertisements naming the company, while breaching the regulations is a criminal offence.

What is the Blue Guide?

The Blue Guide is the MHRA’s guidance on advertising and promotion of medicines in the UK. It explains how the MHRA interprets the advertising provisions of the Human Medicines Regulations 2012, covering topics such as what counts as an advertisement, disease awareness campaigns and advertising to health professionals. It is not law itself, but it shows how the statutory regulator reads the law. The online version was last updated in March 2025.

What must UK pharma promotional material include?

Under the ABPI Code, promotional material for health professionals must include prescribing information (as text, a QR code on printed items, or a single-click link on digital items, depending on format), an adverse event reporting statement pointing to the MHRA Yellow Card scheme, a black triangle where required, and the date it was created or last revised. It must be certified in its final form by a UK-registered doctor or pharmacist.

Can pharma employees share company posts on LinkedIn?

It is risky if the post concerns a prescription-only medicine or an unlicensed use. In two published AstraZeneca cases, the PMCPA ruled that employees liking LinkedIn posts disseminated the content to their connections, some of whom were likely members of the public, breaching the ban on advertising prescription-only medicines to the public. Companies should set clear social media policies and train staff.

How long does a PMCPA complaint take?

According to the PMCPA Annual Report 2025, cases received in 2024 took 52.2 weeks on average to complete. The PMCPA reported that open complaints fell from 155 at the start of 2025 to 81 by the end of the year, and expects completion times to keep falling. Less serious complaints can go through a faster abridged procedure introduced with the 2024 Constitution and Procedure.

Sources

1. legislation.gov.uk, The Human Medicines Regulations 2012, regulation 284: Prescription only medicines, 2012 (as amended)
2. legislation.gov.uk, The Human Medicines Regulations 2012, Part 14: Advertising, 2012 (as amended)
3. legislation.gov.uk, The Human Medicines Regulations 2012, regulation 280: General principles, 2012
4. legislation.gov.uk, The Human Medicines Regulations 2012, regulation 303: Offences, 2012 (as amended)
5. MHRA (GOV.UK), Advertise your medicines, updated 11 April 2025
6. MHRA (GOV.UK), Blue Guide: advertising and promotion of medicines in the UK, updated 28 March 2025
7. MHRA, The Blue Guide: Advertising and Promotion of Medicines in the UK, Third Edition (PDF), 2020
8. MHRA (GOV.UK), MHRA and partners unite to reaffirm prescription weight-loss medicine advertising rules, 26 September 2025
9. ABPI, 2024 ABPI Code of Practice launched, with a new constitution and procedure for the PMCPA, 23 September 2024
10. PMCPA, ABPI Code of Practice for the Pharmaceutical Industry 2024: Introduction, 2024
11. PMCPA, The ABPI Code of Practice for the Pharmaceutical Industry, accessed September 2026
12. PMCPA, 2024 ABPI Code, Clause 5: High Standards and Suitability, 2024
13. PMCPA, 2024 ABPI Code, Clause 6: Information, Claims, Comparisons and Disparagement, 2024
14. PMCPA, 2024 ABPI Code, Clause 8: Certification and Examination, 2024
15. PMCPA, 2024 ABPI Code, Clause 11: Marketing Authorisation and Temporary Supply Authorisation, 2024
16. PMCPA, 2024 ABPI Code, Clause 12: Prescribing Information and Other Obligatory Information, 2024
17. PMCPA, 2024 ABPI Code, Clause 26: Relations with the Public, Including Patients and Journalists, 2024
18. PMCPA, 2024 ABPI Code, Clause 27: Relationships with Patient Organisations, 2024
19. PMCPA, Revised social media guidance published, 4 February 2026
20. PMCPA, PMCPA social media guidance, 2026
21. PMCPA, Can the PMCPA give companies any guidance about using artificial intelligence (AI) to assist in the review of promotional materials?, revised June 2025
22. PMCPA, AUTH/3774/6/23: Complainant v AstraZeneca, completed 21 October 2024
23. PMCPA, CASE/0563/04/25: Complainant v AstraZeneca, completed 17 October 2025
24. PMCPA, New PMCPA Policies June 2025, 1 June 2025
25. PMCPA, Complaints procedure, accessed September 2026
26. PMCPA, Sanctions, accessed September 2026
27. PMCPA, Administrative charges, accessed September 2026
28. PMCPA, PMCPA Annual Report 2025, 2026
29. PMCPA, PMCPA press release 2 February 2026: Case ruled in breach of Clause 2, 2 February 2026
30. PMCPA, PMCPA press release 17 April 2026: Cases ruled in breach of Clause 2, 17 April 2026
31. ABPI, Disclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to grow, 30 June 2026